US Allocates $590 Million to Moderna for Bird Flu Vaccine Development
- The U.S. Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect against bird flu, the pharmaceutical company announced Friday.
- Moderna plans to advance research on the mRNA vaccine into a Phase 3 trial after receiving positive results in earlier phases, which it plans to present at a scientific conference in the near future.
- The Biden administration announced this month that it would invest more than $300 million to help monitor bird flu and prepare for potential spread.
- HHS Secretary Xavier Becerra stated that accelerating the development of new vaccines will allow us to stay ahead and ensure that Americans have the tools they need to stay safe.
Insights by Ground AI
Does this summary seem wrong?
Coverage Details
Total News Sources0
Leaning Left4Leaning Right1Center7Last UpdatedBias Distribution58% Center
Bias Distribution
- 58% of the sources are Center
59% Center
L 33%
C 59%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
